You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Moderate COVID-19

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COVID-19 Trial in Guangzhou (SHEN26 capsule, SHEN26 )

Recruiting
  • COVID-19
  • SHEN26 capsule
  • SHEN26 placebo
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital Of Guangzhou Medical University
Jun 19, 2023

COVID-19 Infection Trial (WPV01, Placebo)

Not yet recruiting
  • COVID-19 Infection
  • (no location specified)
Mar 1, 2023

COVID-19 Trial in Austin (ExoFlo)

Withdrawn
  • COVID-19
  • (no location specified)
Dec 23, 2022

Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder) Trial (MBS-COV, Placebo)

Not yet recruiting
  • Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
  • (no location specified)
Jul 11, 2023

COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2 Trial (Tafenoquine Oral Tablet, Placebo)

Not yet recruiting
  • COVID 19 Disease
  • +4 more
  • Tafenoquine Oral Tablet
  • Placebo
  • (no location specified)
Jul 13, 2023

COVID-19 Trial in Jinan (QLS1128, Placebo)

Not yet recruiting
  • COVID-19
  • Jinan, Shandong, China
    Qilu Pharmaceutical Co., Ltd.
Mar 8, 2023

COVID-19 Trial in Taipei (P1101 (Ropeginterferon alfa-2b), SOC)

Active, not recruiting
  • COVID-19
  • P1101 (Ropeginterferon alfa-2b)
  • SOC
  • Taipei, Taiwan
    National Taiwan University Hospital
Mar 13, 2023

Mild to Moderate COVID-19 Trial in Shenzhen (FB2001, FB2001 )

Recruiting
  • Mild to Moderate COVID-19
  • Shenzhen, Guangdong, China
    Shenzhen Third People's Hospital
Jan 4, 2023

COVID-19 Pneumonia Trial (GST-HG171/Ritonavir, Placebo)

Not yet recruiting
  • COVID-19 Pneumonia
  • (no location specified)
Dec 18, 2022

Cognitive Impairment and Fatigue After Mild to Moderate COVID-19

Recruiting
  • Post COVID-19 Condition
  • +2 more
  • Neuropsychological investigation
  • +3 more
  • Stockholm, Sweden
    Department of Rehabilitation Medicine, Danderyd Hospital
Sep 18, 2023

Infection of Upper Respiratory Tract Caused by 2019-nCoV Trial in Shanghai (SA55 Injection)

Recruiting
  • Infection of Upper Respiratory Tract Caused by 2019-nCoV
  • SA55 Injection
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 12, 2023

COVID-19 Trial in Jinan (QLS1128, Placebo)

Recruiting
  • COVID-19
  • Jinan, Shandong, China
    Qilu Pharmaceutical Co., Ltd.
Jan 15, 2023

COVID-19 Trial in Beijing, Shenzhen (STI-1558, STI-1558 )

Not yet recruiting
  • COVID-19
  • Beijing, China
  • +1 more
Feb 5, 2023

Covid19 Trial in Montréal (Dalcetrapib, Placebo)

Completed
Has Results
  • Covid19
  • Montréal, Quebec, Canada
    Institut de Cardiologie de Montréal
Nov 10, 2022

Mild to Moderate COVID-19 Trial (RAY1216, Placebo)

Not yet recruiting
  • Mild to Moderate COVID-19
  • (no location specified)
Nov 17, 2022

COVID-19 Trial in Brandenburg an der Havel (Palbociclib)

Withdrawn
  • COVID-19
  • Brandenburg an der Havel, Germany
    Universitätsklinikum Brandenburg an der Havel
Nov 3, 2022

COVID-19 Trial in Goyang-si, Incheon (Pyramax)

Completed
  • COVID-19
  • Goyang-si, Gyeonggi-do, Korea, Republic of
  • +1 more
Nov 30, 2022

COVID-19 Trial (Chinese Herb, Placebo)

Not yet recruiting
  • COVID-19
  • Chinese Herb
  • Placebo
  • (no location specified)
Mar 25, 2023

COVID-19 Trial in Guangzhou, Shenzhen, Shijiazhuang (SHEN26 dose 1, SHEN26 dose 2, SHEN26 )

Recruiting
  • COVID-19
  • SHEN26 dose 1
  • +2 more
  • Guangzhou, Guangdong, China
  • +3 more
Jan 4, 2023

SARS CoV 2 Infection Trial in Anniston, Hialeah (ASC10, Placebo)

Not yet recruiting
  • SARS CoV 2 Infection
  • Anniston, Alabama
  • +1 more
Oct 28, 2022

Covid19 Trial (TB006, Placebo)

Withdrawn
  • Covid19
  • (no location specified)
May 11, 2022

COVID-19 Trial in Seoul (Clevudine, Placebo)

Completed
  • COVID-19
  • Seoul, Korea, Republic of
    Korea University Guro Hospital
Jul 20, 2022

COVID-19 Trial (SIM0417, Placebo)

Not yet recruiting
  • COVID-19
  • (no location specified)
Aug 17, 2022

Covid-19 Trial in Grenoble (Mixture 3,6% H2 in N2 (96.4%))

Recruiting
  • Covid-19
  • Mixture 3,6% H2 in N2 (96.4%)
  • Grenoble, France
    CHU de Grenoble Alpes
May 24, 2022

COVID-19 Trial (Meplazumab foe injection, Normal saline)

Not yet recruiting
  • COVID-19
  • Meplazumab foe injection
  • Normal saline
  • (no location specified)
Jan 16, 2023